Clopidogrel Tablets
Myocardial Infarction Prevention
75mg
Utilised to manage platelet activity to alleviate arterial clot formations and support cardiovascular circulation.
From$0.47/ tabletView
Clopidogrel
Clopidogrel is an antiplatelet medicine represented by one 75 mg tablet record. It reduces platelet activation after the body converts it to an active metabolite, an identity that is clinically different from anticoagulants such as factor Xa inhibitors.
Key points
- Clopidogrel irreversibly blocks the platelet P2Y12 ADP receptor after metabolic activation.
- The attached Clopidogrel Tablets record contains one active ingredient at 75 mg.
- It is used in defined coronary, cerebrovascular and peripheral arterial disease settings.
- Bleeding and reduced activation in some CYP2C19 metaboliser profiles are central label considerations.
A prodrug with variable activation
Clopidogrel itself must be metabolised before it can inhibit platelets. Genetic differences and medicines that affect CYP2C19 can reduce formation of the active metabolite. This is why the official label carries a boxed warning about diminished effectiveness in CYP2C19 poor metabolisers.
The catalogue connects the 75 mg tablet with stroke prevention and related cardiovascular uses under blood thinners. These taxonomy links describe clinical contexts, not interchangeable reasons to begin or stop treatment.
What matters around bleeding and procedures
Because platelet inhibition persists for the life of the affected platelet, clopidogrel can lengthen bleeding. A prescriber needs to know about other antiplatelets, anticoagulants, nonsteroidal anti-inflammatory medicines and any planned surgery or dental procedure.
Clopidogrel should not be discontinued casually after a coronary event or stent. The risk created by interruption depends on why it was prescribed and on the timing of the procedure, so any pause requires a coordinated clinical plan.